DHL Group is investing $2 billion through 2030 to grow its life sciences and healthcare logistics business, with $860 million going to North America.

What’s Related

The company announced the plan on Monday, saying the money will go toward expanding cold storage, building new pharma hubs, and adding more temperature-controlled vehicles to support sensitive medical shipments like clinical trials, vaccines, and gene therapies.

“Similar to DHL Group’s purpose of ‘Connecting people, improving lives,’ our strategic investment in life sciences and healthcare is driven by our customers’ mission: delivering essential, often life-saving products to people in need,” said Oscar de Bok, CEO of DHL Supply Chain. “We’re building high-quality, integrated logistics solutions that are as innovative and reliable as the products our customers create — ensuring that patients everywhere receive the right treatment, at the right time, with complete confidence.”

The move is part of DHL’s long-term growth plan, “Strategy 2030.” Of the $2 billion total, 40% will be spent in North America, 25% in both EMEA and Asia Pacific, and 10% in Latin America.

A big part of the investment will go toward expanding cold chain operations, including low—and ultra-low-temperature storage and packaging. DHL says it will also roll out new technology that gives healthcare companies full visibility into shipments so they can monitor compliance and product safety from start to finish.

DHL is bringing all of this under a new brand called DHL Health Logistics, which will simplify global shipping for pharmaceutical, biopharma, and medical customers.

The company already has nearly 600 life sciences and healthcare sites in 130 countries and expects the investment to help drive an extra $5 billion in revenue by 2030.

DHL also recently bought CRYOPDP, a courier specializing in clinical trials and biopharma, to help grow its network and strengthen services for customers working on next-generation therapies.